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Abstract
The origin of several vascular pathologies involves sudden or recurrent oxygen deficiency. In this review, we examine what
the biochemical and molecular responses of the endothelial cells to the lack of oxygen are and how these responses may
account for the features observed in pathological situations, mainly by modifications of cell^cell interactions. Two major
responses of the endothelial cells have been observed depending on the degree and duration of the oxygen deficiency. Firstly,
acute hypoxia rapidly activates the endothelial cells to release inflammatory mediators and growth factors. These
inflammatory mediators are able to recruit and promote the adherence of neutrophils to the endothelium where they become
activated. The synthesis of platelet-activating factor plays a key role in this adherence process. Secondly, longer periods of
hypoxia increase the expression of specific genes such as those encoding some cytokines as well as for the growth factors
platelet-derived growth factor and vascular endothelial growth factor. The transcriptional induction of these genes is
mediated through the activation of several transcription factors, the most important one being hypoxia inducible factor-1.
The link between our knowledge of the signalling cascade of the cellular and molecular events initiated by hypoxia and their
involvement in several vascular pathological situations, varicose veins, tumor angiogenesis and pulmonary hypertension is
discussed briefly. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
By virtue of its location and ability to synthesize
various vasoactive mediators, the vascular endothe-
lium plays a key role in the maintenance of vascular
homeostasis. Indeed, numerous endothelial-derived
products have been shown to regulate platelet, leu-
kocyte or smooth muscle cell functions and distur-
bance of the endothelial metabolism profoundly af-
fects the vascular functions.
Being the ¢rst cell layer in contact with the blood,
endothelial cells have to cope with all changes occur-
ring within the blood. One of these changes is the
variation in the oxygen tension. The metabolic and
molecular changes occurring during hypoxia/reoxy-
genation have been abundantly investigated and re-
viewed and they greatly contributed to the under-
standing of the pathophysiological modi¢cations
observed in ischemic/reperfused organs. However, re-
cently, it has been found that hypoxic conditions by
themselves have profound e¡ects on the endothelial
functions: hypoxia is able to activate the endothelial
cells and thereby initiates a cascade of reactions in-
volving neutrophils and smooth muscle cells. In ad-
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dition, hypoxia directly regulates the expression of
several genes.
In this paper, we review some of the mechanisms
leading to endothelial cell activation which occurs
under hypoxic conditions. We also examine the rele-
vance of such a cascade of reactions induced by hyp-
oxia for the appearance of some physiopathological
modi¢cations observed in vessel walls under ischemic
conditions.
2. Endothelial cell^neutrophil interactions
One of the most spectacular e¡ects of hypoxia on
endothelial cells is to increase their adhesiveness for
neutrophils [1^3]. This adherence is observed both in
vitro and in vivo [4] under hypoxia and does not
require the reoxygenation step.
In general, leukocyte emigration from the blood
stream occurs through a sequential three step process
mediated by several adhesion molecules as well as
chemoattractant/activator molecules [5,6]. The initial
rolling phase is mediated by selectins and consists in
a slowing down of the leukocyte movement at the
surface of the endothelium. Subsequently, ¢rm ad-
herence occurs via the interaction of the leukocyte
L2-integrins with ligands such as ICAM-1 (intercel-
lular adhesion molecule-1). This binding requires ac-
tivation of the integrins by exposure of the neutro-
phils to chemoattractant/activator molecules like
interleukin-8 or platelet-activating factor (PAF).
Finally, transmigration through the endothelium
occurs, triggered by a gradient of chemotactic fac-
tors.
Some molecular basis for hypoxia-induced adher-
ence of neutrophils to endothelial cells has been un-
tangled and the data obtained on HUVEC (human
umbilical vein endothelial cells) are summarized in
Fig. 1. It follows the general pattern mentioned
above and is the consequence of endothelial cell
activation by hypoxia. Activation as used here means
a direct process which does not need gene induc-
tion.
The hypoxia signalling cascade involves di¡erent
Fig. 1. Metabolic and biochemical responses of endothelial cells to hypoxia leading to their activation and to the adherence and acti-
vation of neutrophils. ICAM-1, intercellular adhesion molecule-1; LTB4, leukotriene B4 ; PAF, platelet-activating factor; PGF2K, pros-
taglandin F2K ; PSGL-1, P-selectin glycoligand-1; vWF, von Willebrand factor.
BBAMCR 14629 22-5-00 Cyaan Magenta Geel Zwart
C. Michiels et al. / Biochimica et Biophysica Acta 1497 (2000) 1^102
pathways necessary for a rapid cell activation or for
the regulation of gene expression; it seems to be de-
pendent on the cell type and varies according to the
degree of hypoxia. In di¡erentiated HUVEC exposed
to oxygen de¢ciency, the initiating event of the en-
dothelial cell activation is a decrease in the mito-
chondrial respiratory chain activity [7]. A decrease
in mitochondrial potential has been observed in liver
sinusoidal endothelial cells exposed to hypoxia [8].
Moreover, direct inhibition of the respiratory chain
in HUVEC also leads to enhanced neutrophil adher-
ence as hypoxia [9]. It must, however, be noted that
the inhibition of mitochondrial oxidative phosphor-
ylation does not always recapitulate the e¡ects of
hypoxia. This is particularly true for gene expression
induced by hypoxia inducible factor-1 (HIF-1) (see
below).
Di¡erent second messengers may be responsible
for the hypoxia-induced activation of endothelial
cells. Firstly, a fall in cAMP concentration is ob-
served in hypoxic endothelial cells, which may be
responsible for an increased vascular leakage [10].
Secondly, an increase in the cytosolic calcium con-
centration is observed in di¡erentiated HUVEC
[11,12]. Calcium ion regulates the activity of various
enzymes and is a mediator of signal transduction for
thrombin, histamine or bradykinin stimulation in en-
dothelial cells. An elevated calcium concentration ac-
tivates phospholipase A2 in hypoxic endothelial cells
[13], leading to the synthesis of high amounts of
prostaglandins. Increased PGI2 release from bovine
pulmonary artery endothelial cells [14] and from
HUVEC [15] and increased PGI2 (prostaglandin
I2), PGF2K, PGD2 and PGE2 release from HUVEC
were indeed observed under hypoxia [13], while in
some experimental models, a decrease is observed
[16]. PGF2K seems to be responsible for the chemo-
tactic activity for neutrophils present in hypoxic HU-
VEC-conditioned medium (Arnould, unpublished
data). It was recently suggested that this hypoxia-
induced synthesis of prostanoids also inhibits NO
production via an autocrine negative feedback mech-
anism [17] which could partially explain the fre-
quently observed decrease of EDRF release by endo-
thelial cells in hypoxia. Recently, Schmedtje et al.
[18] have demonstrated that hypoxia induces cyclo-
oxygenase-2 expression via the activation of the NF-
UB p65 transcription factor in human endothelial
cells. These data indicate that, under hypoxia, both
the level of cyclooxygenase and the phospholipase A2
activity increases, which could account for the in-
crease in prostaglandin synthesis in endothelial cells
exposed to hypoxia.
Activation of phospholipase A2 in hypoxic endo-
thelial cells not only allows a large release of prosta-
glandins but also the synthesis of PAF [3,19]. In vivo
and in vitro studies showed that PAF is a neutrophil-
activating agent promoting this adherence to the en-
dothelium after hypoxia or ischemia [2,20]. Di¡erent
structurally unrelated PAF antagonists as well as the
inhibition of PAF synthesis by oleic acid indeed
block neutrophil adherence to hypoxic endothelial
cells [3]. Concomitantly, Pinsky et al. [21] elegantly
demonstrated that hypoxia alone induces a calcium-
dependent exocytosis of the Weibel^Palade bodies.
These organelles, typical of endothelial cells, store
the von Willebrand factor (vWF). This exocytosis
leads to the release of vWF [22] and to the overex-
pression of P-selectin which then sustains neutrophil
binding. This explains why hypoxia-induced neutro-
phil adherence can be blocked by antibodies against
P-selectin [3,23]. In addition to PAF and P-selectin,
the hypoxia-induced neutrophil adherence also re-
quires the neutrophil L2 integrin (CD18) [1,3,23] as
well as the endothelial ICAM-1. Neither ICAM-1
nor E-selectin nor VCAM-1 are upregulated by hyp-
oxia [24]. Hence, it was suggested that the adherence
process was due to its constitutive expression on en-
dothelial cells [3]. The role of another still uncharac-
terized adhesion molecule only expressed on hypoxic
endothelial cells but not on normoxic cells has been
reported [25].
Neutrophils not only adhere but are also activated
when in contact with hypoxic HUVEC. This activa-
tion is characterized by an increased cytosolic calci-
um concentration, by the release of high amounts of
superoxide anion and by the synthesis of leukotriene
B4 [26]. They are also sensitive to hypoxic conditions.
Several authors have reported that hypoxia per se is
able to increase CD18/CD11b expression at the sur-
face of neutrophils [27^29] resulting in an enhanced
adhesion to endothelial cells. On the other hand,
hypoxia has been shown to decrease free radical pro-
duction and cytokine synthesis by neutrophils in re-
sponse to various stimuli [30,31]. It must be noted
that the contact of neutrophils with activated endo-
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thelial cells not only results in adherence and activa-
tion but also in delayed apoptosis, thereby prolong-
ing their useful life [32].
In conclusion, hypoxia per se is able to activate the
endothelial cells as well as to initiate all stages of
recruitment, rolling, adhesion and activation of neu-
trophils in ischemic organs.
In addition to this overall cascade of reactions,
other endothelial cell functions are also modulated
by hypoxia. Endothelial cells maintained under hyp-
oxia for 24 h display a signi¢cant increase in proco-
agulant activity [33] which correlates with a marked
decrease of thrombomodulin expression at the sur-
face of endothelial cells [34]. The expression of the
tissue factor [35] and of some cytokines like interleu-
kin-6 [36,37], interleukin-1K [38], interleukin-8 [39,40]
and MCP-1 (macrophage chemotactic protein-1) [39]
is also enhanced under hypoxic conditions. The pro-
duction of these proin£ammatory cytokines in addi-
tion to the cascade described in Fig. 1 may explain
why an in£ammatory response develops in ischemic
tissues.
3. Tissue remodeling
The vascular tone is regulated under normal con-
ditions through the release by endothelial cells of
both vasorelaxing molecules such as EDRF and
prostacyclin and vasoconstricting agents like endo-
thelin-1 (ET-1). The molecular mechanism beyond
the regulation of the synthesis of these vasoactive
mediators is still under investigation but the best
documented hypothesis suggests the presence of ‘me-
chanosensors’ which would sense the shear stress
undergone by the cells [41].
Hypoxia di¡erently a¡ects these two types of mol-
ecules creating conditions favorable to vasoconstric-
tion [42]. Indeed, the basal and agonist-stimulated
release of EDRF by endothelial cells is quickly in-
hibited by hypoxia [43,44] and the NO production
remains very low even after long periods of hypoxia
(24^48 h). This seems to be due to a decrease in the
endothelial constitutive NO synthase expression
[45,46]. Recent data however indicate that, unlike
endothelial constitutive NO synthase, inducible NO
synthase is induced by hypoxia in pulmonary artery
endothelial cells [47]. The overall result of these
changes, i.e. the e¡ect of hypoxia on NO production,
thus remains highly controversial.
In contrast, hypoxia generally enhances the release
of ET-1 by endothelial cells in vitro [48,49] but this
depends on experimental conditions since, in two
cases, a decrease has been reported [50,51]. In vivo,
an increase in ET-1 circulating level is also observed
and this was correlated with an induction of ET-1
gene transcription in lungs [52].
The e¡ect of hypoxia on the release of mitogenic
molecules for smooth muscle cells is also well evi-
denced. Experimentally, it was shown that short-
term hypoxic endothelial cell-conditioned medium in-
duces the proliferation of smooth muscle cells. By the
use of cyclooxygenase inhibitors and neutralizing
antibodies, PGF2K and basic ¢broblast growth factor
(bFGF) have been identi¢ed as being the mediators
of this e¡ect [53]. bFGF seems to be released from
intracellular stores by hypoxic endothelial cells since
there is no induction of its synthesis by hypoxia [54].
Other mitogens, such as platelet-derived growth fac-
tor-B (PDGF-B), have also been detected in sus-
tained hypoxia [54]. The presence of PDGF and of
ET-1, which also has mitogenic properties for
smooth muscle cells, contributes to the pro-prolifer-
ative activity present in conditioned media from en-
dothelial cells undergoing a sustained hypoxia [55].
In conclusion, the increased production of these dif-
ferent mitogens combined with the suppression of
endothelial NO synthase would be expected to accel-
erate smooth muscle cell growth and to induce vas-
cular remodeling. In addition to increase the release
of growth factors, hypoxia stimulates the production
of some extracellular matrix proteins, such as throm-
bospondin-1 in human endothelial cells [56]. Throm-
bospondin-1 modulates smooth muscle cell prolifer-
ation and migration and may be a negative regulator
of angiogenesis [57]. Chronic in vivo hypoxic expo-
sure indeed induces medial hypertrophy of pulmo-
nary vessels [58^62]. Cell proliferation and matrix
deposition in hypoxia re£ects an imbalance between
pro-proliferative and anti-proliferative stimuli, most
of them derived from the endothelium.
Recent ¢ndings from Kourembanas’ laboratory
suggest that this proliferative response is regulated
by a negative feed back loop mediated through
smooth muscle cell-derived CO. They observed an
increased CO production in smooth muscle cells
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under hypoxia which is the result of the transient
induction by hypoxia of heme oxygenase-1 expres-
sion [63]. CO released by hypoxic smooth muscle
cells was shown to be able to decrease the hypoxia-
induced transcription of PDGF-B and ET-1 in endo-
thelial cells by increasing their cGMP content. This
cascade eventually inhibits smooth muscle cell prolif-
eration initiated by hypoxia [64]. In addition, the
increased CO release by smooth muscle cells under
hypoxic conditions was shown to be directly respon-
sible for smooth muscle cell growth inhibition [65].
Fig. 2 summarizes some of the interplay between
endothelial and smooth muscle cell mediators under
hypoxia.
Endothelial cell proliferation itself is also a¡ected
by hypoxia. The most potent and speci¢c mitogen
for the endothelial cells is vascular endothelial
growth factor (VEGF). It is known to initiate angio-
genesis in vivo [66]. Its expression is upregulated by
hypoxia in numerous cell types including endothelial
cells [67,68]. In addition, an increased expression of
the VEGF receptor Flt-1 [69] and a functional upre-
gulation of the VEGF receptor KDR or Flk-1 by
hypoxia [70] have been reported in response to hyp-
oxia, which can be responsible for the stronger
VEGF-induced mitogenic response of hypoxic endo-
thelial cells compared to normoxia.
The release of all these cytokines and growth fac-
tors by cells like the endothelial cells is generally the
result of a complex cascade of processes which ends
with the activation of transcription factors. Some of
them have been found to be activated under hypoxic
conditions but not by the inhibition of mitochondrial
respiration: this is the case for AP-1 [71], nuclear
Fig. 2. Interactions between endothelial cells and smooth muscle cells under hypoxia. bFGF, basic ¢broblast growth factor; ET-1, en-
dothelin-1; HO-1, heme oxygenase-1; PDGF-B, platelet-derived growth factor-B; PGF2K, prostaglandin F2K.
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factor-interleukin-6 (NF-IL-6) [36], NF-UB-like
[37,39,72] and Egr-1 [73] (see Faller et al. for a review
[74]). However, the prototype of the transcription
factors regulated by hypoxia is HIF-1. HIF-1 is a
ubiquitous basic helix-loop-helix PAS heterodimer
which is activated by hypoxia [75^77]. It is composed
of the two subunits, HIF-1K and HIF-1L or ARNT
(aryl/hydrocarbon receptor nuclear translocator), the
¢rst being upregulated by hypoxia. Very little is
known about the mechanisms of oxygen sensing,
the signalling pathway and the subsequent activation
of HIF-1. Possible mechanisms include protein
stability and degradation by proteasome, phosphor-
ylation, redox processes and Hsp90 binding regulat-
ing intracellular localization and more than one
could be involved [78]. Moreover, a major line of
research is the identi¢cation of the cellular oxygen
sensor. Redox processes, for example involving
H2O2, initiated by a postulated heme oxygen sensor
have been proposed [79^81]. The mitochondrion,
which generates reactive oxygen species in higher
amounts under hypoxic conditions, is another possi-
ble candidate [82]. Further investigations are still
needed to elucidate the mechanism leading to the
hypoxic activation of HIF-1.
Recent ¢ndings identi¢ed the presence of HIF-1
binding sites in the 5P or 3P £anking regions of the
genes encoding erythropoietin [83], VEGF [67], heme
oxygenase [84], VEGF receptor Flt-1 [69], glucose
transporter Glut-1 [85] and several glycolytic en-
zymes [86] as well as for the lactate dehydrogenase
A [87]. However, the hypoxia-dependent increase in
VEGF expression seems to be controlled both at the
transcriptional level and at the level of mRNA stabil-
ity [88,89]. It must be noted that recently, a novel
bHLH-PAS factor, termed EPAS-1 [90] or HIF-2K
has been described which is very similar to HIF-1K
and forms heterodimers with ARNT and is activated
by hypoxia. Interestingly, its expression is abundant
in endothelial cells. The endothelial-speci¢c tyrosine
kinase tie-2 [90] and VEGF [91] were identi¢ed as
target genes of HIF-2. The essential role of HIF-1
during development was demonstrated by major vas-
cularization defects and abnormal neural fold forma-
tion in HIF3=3 embryos [92,93]. On the other hand,
EPAS-1 de¢cient mice display normal morphological
development of the circulatory system but die at mid-
gestation due to a profound defect in catecholamine
production [94]. All together, these results indicate
that both transcription factors play an essential but
Fig. 3. Transcriptional responses of endothelial cells to hypoxia. HIF-1/2, hypoxia inducible factor-1/2; NF-UB, nuclear factor-UB; IL-
6, interleukin-6; IL-8, interleukin-8; COX-2, cyclooxygenase-2; VEGF, vascular endothelial growth factor; iNOS, inducible NO syn-
thase; Glut-1, glucose transporter-1; PGK-1, phosphoglycerate kinase-1; Flt-1, VEGF receptor Flt-1 ; tie-2, tie-2 tyrosine kinase recep-
tor.
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completely distinct role in embryo development. Fig.
3 schematically illustrates the e¡ect of hypoxia on
gene transcription in endothelial cells.
Taken together, these results indicate that hypoxia
strongly a¡ects the regulatory pathways of endothe-
lial cells as well as of smooth muscle cells, leading to
the activation of several transcription factors and to
the release of cytokines and growth factors. The end
result is the formation of conditions favorable to
vasoconstriction and proliferative activity, participat-
ing in the remodeling of the vascular wall.
4. Physiological relevance
The ¢nding that the endothelial expression of
some growth factors, cytokines as well as other genes
is in£uenced by variations in oxygen concentration
has obvious physiological implications. Two main
cascades of reactions have been characterized de-
pending on the duration of the oxygen de¢ciency.
Following acute hypoxia, endothelial cells become
activated and neutrophil adherence is observed.
One consequence of this process is the development
of a local in£ammatory reaction in ischemic organs
which is then made worse if reperfusion occurs.
When chronic hypoxic conditions persist then the
expression of growth factors, cytokines and pro-co-
agulation molecules is increased. Several pathological
conditions are known to be linked to hypoxic con-
ditions. Three of them are brie£y discussed.
First, blood stasis is a situation commonly associ-
ated with chronic venous insu⁄ciency. It leads to the
development of ischemic conditions in leg veins. The
alterations observed in the varicose vein wall could
be the result of the in¢ltration of activated neutro-
phils after their adherence to the hypoxic endothe-
lium by the mechanism described here and from the
hypoxia-induced release by endothelial cells of
growth factors stimulating the proliferation of
smooth muscle cells. Such a process would have to
be steadily repeated over a long period of time and
superimposed on other factors in order to bring irre-
versible changes as the ones observed in varicose
veins [95,96].
Second, adaptation to hypoxia represents a key
step in tumor progression. On the one hand, these
conditions induce the activation of HIF-1 allowing
the cells to survive via an adaptive modi¢cation of
their energetic metabolism: HIF-1 increases the ex-
pression of several glycolytic enzymes and hence the
glycolysis rate [97]. HIF-1 has actually been found to
be overexpressed in various human tumor types in
comparison with the respective normal tissue [98].
On the other hand, HIF-1 is involved in the estab-
lishment of vascular supply. This neoangiogenesis is
thought to be triggered by growth factors released by
the tumor itself becoming hypoxic while enlarging. In
order for tumors to grow, they must become vascu-
larized [99]. In addition, vascularization enhances the
metastasis properties of the tumor [100]. The over-
expression of VEGF, through HIF-1 activation, is
certainly one of the main factors involved in this
process [101,102]. VEGF displays strong angiogene-
sis properties and VEGF mRNA is substantially up-
regulated in most tumors. A correlation between
VEGF expression and microvessel density is ob-
served in several malignancies [103]. Based on this
knowledge, approaches utilizing hypoxia-responsive
elements for HIF-1 are now being developed to tar-
get the expression of therapeutic genes to tumor cells
[104,105].
Third, pulmonary hypertension is a frequent he-
modynamic complication associated with respiratory
system disorders. Chronic alveolar hypoxia is the
main determinant of the increase in pulmonary vas-
cular resistance due to persistent vasoconstriction
and vascular structural remodeling [106,107]. Short
term exposure of the pulmonary circulation to a re-
duced level of oxygen tension both in vitro and in
vivo elicits an immediate vasoconstrictive response
probably through potassium channel inhibition in
smooth muscle cells. Under conditions of chronic
alveolar hypoxia, structural remodeling of the pul-
monary vasculature occurs with medial smooth
muscle cell hypertrophy and proliferation and abnor-
mal deposition of extracellular matrix components.
Growth factors such as ET-1 which can be released
by hypoxic endothelial cell or smooth muscle cells
may participate in this remodeling [52]. Moreover,
a critical role for HIF-1 in the pathogenesis of pul-
monary hypertension has recently been reported
[108].
Our knowledge of the transduction cascade initi-
ated by hypoxia leading either to direct activation or
to the regulation of gene expression is detail. In par-
BBAMCR 14629 22-5-00 Cyaan Magenta Geel Zwart
C. Michiels et al. / Biochimica et Biophysica Acta 1497 (2000) 1^10 7
allel, the involvement of hypoxic conditions and the
role played by cell ‘activation’ induced by oxygen
deprivation in several pathological situations be-
comes clearer. However, many questions are still
open. What is the threshold of oxygen tension re-
sponsible for the activation of the endothelial cells
in vivo? What is the duration or the number of hyp-
oxic events needed for irreversible alterations of the
tissue? One last stimulating question raised by these
discoveries is whether we can in£uence the overall
process in patients. Some of the drugs used in the
treatment of the peripheral ischemia or in varicose
veins have been tested and found to be protective for
the hypoxia-induced activation of endothelial cells in
vitro. However, the question of the potency of these
drugs or of other newly designed molecules for en-
dothelial protection against ischemic conditions and
via the same mechanism in patients is still unan-
swered. This observation by itself would justify fur-
ther investigation to understand the role of hypoxia
in these pathologies.
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